CGTLive’s Weekly Rewind – February 10, 2023
Review top news and interview highlights from the week ending February 10, 2023.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Tecartus Shows Overall Survival Benefit for R/R B-ALL in 3-Year Follow-up Data
The updated data included a median overall survival of 26 months after treatment with brexu-cel.
2. Sham Mailankody, MBBS, on Further Research With ALLO-715
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
3. IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDA
The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.
4. Raj Mehra, PhD, and Krishna Subramanian, PhD, on Parkinson Disease Gene Therapy Mouse Studies
Mehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.
5. First Patient with B-cell Lymphoma Dosed With Allogeneic NK CAR T Therapy
The FDA cleared Century’s IND for CNTY-101 in August 2022.
The Challenges of Gene Therapy Approaches in Advanced Muscular Dystrophy
September 13th 2024Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa, discussed his mouse model research into the pathophysiology of muscular dystrophy and how it relates to gene therapy approaches.
